Cytel designed and led TOGETHER trial wins Clinical Trial award
Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills
Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate (AIAC) both with global intellectual property rights
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
For the first time in India – fast, precise and efficient calibration of multi-channel micropipettes
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
The new logo is a refreshing change from the version that has served Hetero well for three decades. And yet its reflection can be seen in the new version
Subscribe To Our Newsletter & Stay Updated